Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 6/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.35 |
| ▸ | CNR2 | P34972 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL964902 | 1.00 | HDAC3 (0.35) | HDAC3HDAC1HDAC2HDAC6HDAC4 | |
| SCHEMBL964275 | 0.88 | ELANE (0.32) | CNR2POLBCASP6SMN1; SMN2ALDH1A1 | |
| SCHEMBL964274 | 0.88 | ELANE (0.32) | CNR2POLBCASP6SMN1; SMN2ALDH1A1 | |
| SCHEMBL963196 | 0.87 | PTAFR (0.36) | PPARG | |
| SCHEMBL963198 | 0.87 | PTAFR (0.36) | PPARG | |
| SCHEMBL963900 | 0.87 | PPARG (0.43) | CNR2PPARGCNR1 | |
| SCHEMBL963901 | 0.87 | PPARG (0.43) | CNR2PPARGCNR1 | |
| SCHEMBL27793925 | 0.86 | PPARG (0.32) | HDAC3HDAC1HDAC2HDAC6HDAC4 | |
| SCHEMBL963892 | 0.86 | POLB (0.35) | HDAC3HDAC1HDAC2HDAC6HDAC4 | |
| SCHEMBL963893 | 0.86 | POLB (0.35) | HDAC3HDAC1HDAC2HDAC6HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | HDAC3 131/4885HDAC1 108/4885HDAC2 333/4885 |
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | HDAC3 103/4885HDAC1 338/4885HDAC2 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.